Cambridge, UK – 14 September 2021 – Cresset Discovery Services, provider of contract research services for early phase of drug discovery, has announced it will collaborate with the University of Newcastle, Australia, to focus on drug reprofiling against oncology targets. The work will build on research led by award-winning molecular biologist, Associate Professor Nikola Bowden. Nikola is […]

SANTA FE, N.M., USA, & KYIV, Ukraine – OpenEye Scientific and Enamine, a leading global provider of billions of new screening compounds to the drug discovery market, are partnering to enable faster and more accurate virtual screening of ultra-large compound libraries through access to innovative software. Using Orion®, OpenEye’s cloud-native molecular design platform, scientists can: […]

Innovative predictive methods support virtual screening and compound design in the absence of 3D structure data CAMBRIDGE, UK: Optibrium Ltd, a developer of software for drug discovery, today announced the release of the latest version of StarDrop™, its comprehensive software platform for small molecule design, optimisation and data analysis. StarDrop is used by more than 160 […]

DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry, has commenced a project with the University of Cambridge’s Innovation Centre in Digital Molecular Technologies (iDMT), an open innovation research centre co-funded by the University of Cambridge, AstraZeneca, Shionogi, and the European Regional Development Fund. DeepMatter will provide its DigitalGlassware® platform to iDMT as part of the […]

Cambridge, UK – 21 July 2021 – Cresset, innovative provider of outstanding software for molecule discovery and design, is pleased to announce that OncoArendi Therapeutics SA (WSE: OAT), a biotechnology company which specializes in the discovery and development of new drugs, has licensed Flare™ for use in its internal development programs. Cresset software uses its proprietary descriptors of […]

DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry, is pleased to announce that Bryn Roberts has been appointed to the Board as Non-Executive Director with effect from 1 August 2021. Bryn brings a wealth of experience in the pharmaceutical sector having spent 15 years at Roche, the Swiss multinational healthcare company. He is […]

I am delighted to announce that Flare™ V5 is now available. This release of Cresset’s comprehensive platform for drug design features new and enhanced science, integration of ligand- and protein-based approaches and new and improved GUI features to increase usability. Cutting edge QSAR methods With this release, Flare has evolved from a structure-based solution into a comprehensive drug […]

Partnership will enable R&D organizations to accelerate innovation with data science technologies. Toronto, CANADA — ACD/Labs, a leading provider of scientific informatics technologies for molecular characterization, today announced a partnership with Science Data Experts (SDE). Together, ACD/Labs and SDE will use their experience and expertise to enable life sciences organizations to implement a variety of machine […]

11 Billion Novel Molecules: CHEMriya – OTAVA’s On-Demand Chemical Space VAUGHAN, Ontario and SANKT AUGUSTIN, Germany, June 9, 2021 /PRNewswire/ — Today, Canadian-based compound specialist OTAVA (aka OTAVAchemicals) and German frontrunner cheminformatics firm BioSolveIT announce the release of a new, multibillion-sized pool of on-demand chemicals, available for therapeutic R&D. “CHEMriya” — alluding to Mriya, the Ukrainian word for “dream” […]

Industry-leading 3D ligand-based design approaches from BioPharmics will be available in StarDrop, Optibrium’s small molecule design and optimisation software. CAMBRIDGE, UK: Optibrium Ltd and BioPharmics LLC, leading providers of software and computational solutions for drug discovery, today announce their partnership. The collaboration will combine industry-leading computational design solutions with advanced interactive user interfaces, engaging with experimental […]